Clinical trials: Alzheimer's Type
Alzheimer's Type Dementia
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release to the currently marketed formulation of 10 mg donepezil immediate release in patients with severe Alzheimer's disease.
- Trial name
- NCT01539031
- Testing
- E2020
- Where
- 54 sites in Japan
- Volunteers
- 351 people
- Sponsor
- Eisai Co., Ltd.
Dementia, Alzheimer Type
Project COPE:Managing Dementia at Home
This study tests the effectiveness of an in-home intervention to reduce upset and burden among family caregivers, and decrease nursing home placement.
- Trial name
- NCT00259454
- Testing
- In-home intervention
- Where
- United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Alzheimer Disease, Dementia
Development of NIC5-15 in the Treatment of Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of NIC5-15in the treatment of Alzheimer's Disease.
- Trial name
- NCT00470418
- Testing
- NIC5-15
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Office of Research and Development
Alzheimer Disease
Far Infrared Treatment for Alzheimer's Disease
Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.
- Trial name
- NCT00599469
- Testing
- Far Infrared Radiation (5μm to 20μm wavelength)
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- GAAD Medical Research Institute Inc.
Alzheimer Disease, Dementia of Alzheimer Type
Assess Fibrin in Brains With AD/ADRD
The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.
- Trial name
- NCT05336695
- Testing
- PET/MR Imaging, 64Cu-FBP8
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT04623242)
- Testing
- Gantenerumab, Solanezumab
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Early Onset, Alzheimer Disease
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks
This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and…
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Disease, Late Onset, Dementia, Alzheimer Type
- Trial name
- EOAD-Subtype (NCT03153371)
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Alzheimer's Disease
CPC-201 Alzheimer's Disease Type Dementia: PET Study
The purpose of this study is to compare the effect of low and high dose CPC-201 on brain function including cerebral acetylcholinesterase (AChE) activity measured by positron emission tomography (PET).
- Trial name
- NCT02860065
- Testing
- CPC-201, Positron emission tomography (PET)
- Where
- United States
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Alzheimer Dementia, Alzheimer Disease
Treating Hyperexcitability in AD With Levetiracetam
The aim of this study is to explore the relationship between cortical hyperexcitability, abnormalities of brain network function, and cognitive dysfunction in human patients with AD and whether administration of the antiepileptic…
- Conditions
- Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
- Trial name
- LeAD (NCT03875638)
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Alzheimer Disease, Mild Cognitive Impairment
tDCS and Cognitive Training for Mild Cognitive Impairment and Alzheimer's Dementia
There are currently no disease-modifying treatments for cognitive and behavioral symptoms associated with early clinical Alzheimer's disease (AD), and only minimally effective symptomatic treatments are available.
- Trial name
- NCT04507815
- Testing
- Active Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Alzheimer Disease
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
- Trial name
- NCT00041678
- Testing
- aripiprazole
- Where
- 6 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of…
- Trial name
- NCT04971733
- Testing
- E2814
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Eisai Inc.
Dementia of the Alzheimer Type
Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI
The study aims to detect the effect of a structured cognitive rehabilitation program, teh stage specific intervention STACog, on cognitive performance and functional activation in fMRI in a group of patients with mild cognitive…
- Trial name
- ECIF (NCT01329601)
- Testing
- StaCog, stage specific cognitive Intervention, booklet based training
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- University of Rostock
Cognitive Decline, Mild, Alzheimer Disease
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
The goal of this placebo-controlled double-blind Phase 2 clinical trial is to test in people with early Alzheimer's Disease. The main questions it aims to answer are: Does treatment with fasudil, a ROCK-inhibitor, lead to…
- Trial name
- FEAD (NCT06362707)
- Testing
- Fasudil
- Where
- 6 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Helse Stavanger HF
Dementia, Dementia, Mixed
Uppsala-Dalarna Dementia and Gait Project
UDDGait™ is a multidisciplinary research project with the overreaching goal of providing an aid for early identification of cognitive impairment and risk of dementia development, thereby providing a basis for adequate symptom…
- Conditions
- Dementia, Dementia, Mixed, Dementia Senile, Dementia of Alzheimer Type
- Trial name
- UDDGait™ (NCT05893524)
- Testing
- Timed Up-and-Go (TUG single-task), Timed Up-and-Go dual-task (TUGdt), Clinical functional assessment
- Where
- 2 sites in Sweden
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Dalarna University
Dementia of Alzheimer Type
Donepezil Treatment of Psychotic Symptoms in Dementia Patients
Conventional psychotropic medications may be used to treat behavioral disturbances and psychotic symptoms in patients with dementia and they are the drugs of choice for treating delusions and hallucinations.
- Trial name
- NCT00190021
- Testing
- donepezil
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Beersheva Mental Health Center
Mild Cognitive Impairment, Alzheimer Disease 1
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
The purpose of this study is to assess the safety and feasibility of administering standard of care monoclonal antibody (mAb) infusion therapy in combination with opening the blood-brain barrier with the Exablate Model 4000 Type…
- Trial name
- NCT05469009
- Testing
- Aducanumab, Exablate Model 4000 Type 2, Lecanemab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Ali Rezai
Dementia, Alzheimer Type, Mild Cognitive Impairment
Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease
This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits.
- Conditions
- Dementia, Alzheimer Type, Mild Cognitive Impairment, Cardiac Amyloidosis
- Trial name
- NCT07154394
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital, Essen
Alzheimer's Disease
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
This was a multicenter, prospective, phase IV study evaluating safety, tolerability and effectiveness of rivastigmine 27 mg -15 cm^2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per…
- Trial name
- NCT02989402
- Testing
- Rivastigmine
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
This study will evaluate the long-term safety and efficacy of AXS-05 in subjects with Alzheimer's disease (AD) agitation.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
- Trial name
- ACCORD-2 (NCT04947553)
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 47 sites in United States, Canada and 1 more
- Volunteers
- 456 people
- Sponsor
- Axsome Therapeutics, Inc.